PDL BioPharma, Inc.
http://www.pdl.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From PDL BioPharma, Inc.
New Drugs For Gastric Cancer, Liver Disease Among 14 Products Heading For EU Approval
Two orphan drugs are among a host of products that the European Medicines Agency’s human medicines committee has OKd for pan-EU approval.
Fresenius Follows US Denosumab Filing With EU Acceptance
Fresenius Kabi’s denosumab biosimilar filing has been accepted by the European Medicines Agency, coming hot on the heels of a US submission.
Fresenius Debuts Subcutaneous Tocilizumab Biosimilar In US
Fresenius Kabi has become the first firm to market a subcutaneous tocilizumab biosimilar in the US, introducing an SC version of its Tyenne rival to Actemra just a couple of months after the intravenous launch.
The View From The Top: European CEOs Highlight Industry Priorities
At a high-profile panel closing out Medicines for Europe’s 30th annual conference in Dublin, six industry leaders set out their views on key topics including pricing, regulation, sustainability, and stakeholder communication.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Eos Biotechnology, Inc.
- LENSAR, Inc.
- Noden Pharma DAC
- Noden USA
- Protein Design Labs, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice